Back to today’s briefing

Story perspectives

Study Reveals V1 and V3 Variants Shape Lung Cancer Outcomes

9/24/2025

23 5

Summary

Story summary

EML4-ALK fusion variants V1 and V3 in lung adenocarcinoma act as distinct oncogenes, shaping outcomes.
Deutsches Krebsforschungszentrum (DKFZ) and Stanford University used CRISPR/Cas9 to model V1 and V3.
V3 tumors grew larger and faster, shortening survival vs. V1.
Drug sensitivity differed; V1 was more responsive to lorlatinib, while V3 showed resistance.
Genetic alterations, including tumor suppressor mutations, further influenced responses.

1 of 1

Story summary

EML4-ALK fusion variants V1 and V3 in lung adenocarcinoma act as distinct oncogenes, shaping outcomes.
Deutsches Krebsforschungszentrum (DKFZ) and Stanford University used CRISPR/Cas9 to model V1 and V3.
V3 tumors grew larger and faster, shortening survival vs. V1.
Drug sensitivity differed; V1 was more responsive to lorlatinib, while V3 showed resistance.
Genetic alterations, including tumor suppressor mutations, further influenced responses.